IDEAYA Biosciences (NASDAQ: IDYA) announced that its Phase 1/2 clinical trial evaluating IDE892, an MTA-cooperative PRMT5 inhibitor, has initiated Part ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA